<DOC>
	<DOCNO>NCT00485329</DOCNO>
	<brief_summary>The study objective evaluate DermastreamTM - EnzystreamTM system safety , tolerability efficacy , potent method debridement nonhealing low extremity chronic venous ulcer patient .</brief_summary>
	<brief_title>Assessment Safety Efficacy DERMASTREAM™ - ENZYSTREAM™ System Treatment Chronic Venous Ulcers</brief_title>
	<detailed_description>This phase I/II prospective , randomize , double blind , placebo control , dose escalating , three patient-group study , evaluate safety efficacy DermaStream™ - EnzyStream™ System non-healing low extremity chronic venous ulcer patient . The DermaStream™ - EnzyStream™ System evaluate continue stream 3 different dos EnzystreamTM ( papain base ) solution give escalate order ( 15,000 , 30,000 60,000 papain USP units/ml ) 5 consecutive treatment day . Each treatment session last 6 hour . This study Multi center trial . It anticipate three ( 3 ) site enroll subject study . Overall , forty eight ( 48 ) patient recruit , randomly allocate placebo EnzyStream™ treatment study dose group prior EnzyStream™ administration . The ratio drug placebo treat patient 4 ; 1 , namely 12 patient administer EnzyStream™ solution 4 patient placebo treat three respective EnzyStream™ dose group . Treatment start low dose ( 15,000 papain USP units/ml ) administer 6 hour period follow saline wash additional half hour . The treatment dose increase next high dose , next patient group follow safety analysis , procedure repeat . The treatment period follow 3 month follow period . During follow period patient observe every 2 week first month month ( every 20 day ) 2 additional month ( allow time window ± 3 day ) .</detailed_description>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Varicose Ulcer</mesh_term>
	<criteria>1 . Patient must venous leg ulcer 2 . Participants , either men woman 18 85 year age . 3 . Clinical presentation venous insufficiency demonstrate Doppler 4 . AnkleBrachial Index &gt; 0.7 Doppler 5 . Good palpable pulse Posterior Tibial Dorsalis Pedis artery . 6 . Wound present least 6 week prior enrolment . 7 . Wound length range : 1.5 7 centimeter . 8 . The necrotic tissue area least 20 % wound area . ( clinical evaluation , i.e. , inspection ) . 9 . Wound San Antonio classification : Grade 1 2 , Stage A B . 10 . Wound location : foot calf , location device attach properly . 11 . Participant understands nature procedure provide write informed consent prior study procedure . 12 . Women child bear potential must use adequate birthcontrol precaution . 1 . Documented sensitivity Papain , medical history record . 2 . Patients need surgical debridement . 3 . Patients general skin disorder ( Psoriasis , Peniculitis ect ) might deteriorate result local trauma . 4 . Patients skin disorder unrelated ulcer present adjacent wound . 5 . Pain sensation completely absent ( wound area anesthetic ) . 6 . Patients renal failure . ( Cr &gt; 2 mg/dl ) . 7 . Patients impaired hepatic function ( ALT , AST GGT 2fold high normal upper limit value ) . 8 . Patients Hypoalbuminemia : ( Albumin &lt; 2gr/dl ) . 9 . Patients general Immunological disorder might deteriorate result local trauma . 10 . Rightside congestive heart failure ( CHF ) edema legs : ( NYHA class 2 high see APPENDIX 5 ) . 11 . Participation another clinical trial within 1 month prior start study . 12 . Subject unwilling unable comply requirement protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>May 2010</verification_date>
	<keyword>Chronic Wounds , Venous Ulcers , Papain , Debridement , Continuous stream</keyword>
	<keyword>DermaStream-EnzyStream</keyword>
</DOC>